This is a protocol for a Cochrane Review (intervention). The objectives are as follows:
To assess the effectiveness and safety of adjuvant EGFR tyrosine kinase inhibitors (TKIs) in patients with resected stage I to III non-small-cell lung cancer (NSCLC) harbouring an activating EGFR mutation.
This is a protocol.